Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

B cells are frequently found in the margins of solid tumours as organized follicles in ectopic
lymphoid organs called tertiary lymphoid structures (TLS),. Although TLS have been found to …

Natural killer (NK) cells play indispensable roles in innate immune responses against tumor
progression. To depict their phenotypic and functional diversities in the tumor …

Cryptic promoters within transposable elements (TEs) can be transcriptionally reactivated in
tumors to create new TE-chimeric transcripts, which can produce immunogenic antigens. We …

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …

Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer
management. Nonetheless, not all patients benefit from such therapies because they fail to …

DNA methyltransferases are an essential class of modifiers in epigenetics. In mammals,
DNMT1, DNMT3A and DNMT3B participate in DNA methylation to regulate normal …

Although approved programmed cell death protein (PD)-1 inhibitors show durable
responses, clinical benefits to these agents are only seen in one-third of patients in most …